{"id":4214,"date":"2022-05-20T12:00:14","date_gmt":"2022-05-20T03:00:14","guid":{"rendered":"https:\/\/www.peptide.co.jp\/en\/?p=4214"},"modified":"2023-08-29T10:13:29","modified_gmt":"2023-08-29T01:13:29","slug":"5033","status":"publish","type":"post","link":"https:\/\/www.peptide.co.jp\/en\/new-product\/5033.html","title":{"rendered":"Novel IgG Binding Peptides for Antibody Purification"},"content":{"rendered":"

3426-v IgGBP-17A; Suitable for Human IgG Purification<\/h3>\n

\u3000
\n\u3000
\n\"IgGBP-17A\u306e\u69cb\u9020\"
\n\u3000
\n\u30fb High affinity with Fc region of human IgG1, IgG2, and IgG4 (K<\/i>d<\/sub>: 95 nM for human IgG1)
\n\u30fb No cross-reactivity with other species (lower affinity with rabbit IgG)<\/font>
\n\u30fb Human IgG specific affinity column can be easily prepared by immobilizing to NHS column
\n\u30fb Peptide moiety is stable against repeated base treatment
\n\u30fb Binding capacity:
\n\u3000\u300013.2 mg human IgG\/1 mL of gel (1 mg peptide immobilized to 1 mL NHS column)
\n\u3000\u300037.1 mg human IgG\/1 mL of gel (3 mg peptide immobilized to 1 mL NHS column)
\n\u3000
\n\u3000
\n\u3000<\/p>\n

3427-v IgGBP-Z34CA; Suitable for IgG Purification<\/h3>\n

\u3000
\n\u3000
\n\"IgGBP-Z34CA\u306e\u69cb\u9020\"
\n\u3000
\n\u3000
\n\u30fb High affinity with Fc region of IgG (K<\/i>d<\/sub>: 24 nM for human IgG1, 89 nM for rat IgG2c)
\n\u30fb IgG specific affinity column can be easily prepared by immobilizing to NHS column
\n\u30fb Peptide moiety is stable against repeated base treatment
\n\u30fb Binding capacity: 3.2 mg human IgG\/1 mL of gel (1 mg peptide immobilized to 1 mL NHS column)
\n\u3000
\n\u3000<\/p>\n\n\n\n\n\n
Code<\/td>\nProduct Name<\/td>\nQuant<\/td>\n<\/tr>\n
3426-v<\/a><\/td>\nIgGBP-17A<\/td>\n1 mg<\/td>\n<\/tr>\n
3427-v<\/a><\/td>\nIgGBP-Z34C<\/td>\n1 mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u3000
\n\u3000
\nThese products are sold under a patent license from Kagoshima University.
\nTheir use for radioactive labeling to antibodies is restricted by patent agreements.<\/font>
\n\u3000<\/p>\n

<\/div>\n
<\/div>\n

Feel free to contact us if you have any questions.
\n<\/a><\/Div><\/p>\n","protected":false},"excerpt":{"rendered":"

3426-v IgGBP-17A; Suitable for Human IgG Purification \u3000 \u3000 \u3000 \u30fb High affinity with Fc region of human IgG1, IgG2 […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts\/4214"}],"collection":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/comments?post=4214"}],"version-history":[{"count":4,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts\/4214\/revisions"}],"predecessor-version":[{"id":4925,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/posts\/4214\/revisions\/4925"}],"wp:attachment":[{"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/media?parent=4214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/categories?post=4214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.peptide.co.jp\/en\/wp-json\/wp\/v2\/tags?post=4214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}